Compass Therapeutics, Inc. $CMPX Position Raised by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP boosted its position in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 65.4% in the first quarter, HoldingsChannel.com reports. The firm owned 940,538 shares of the company’s stock after purchasing an additional 371,791 shares during the quarter. Compass Therapeutics comprises approximately 1.6% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 18th biggest holding. Seven Fleet Capital Management LP’s holdings in Compass Therapeutics were worth $4,975,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CMPX. DV Trading LLC boosted its stake in Compass Therapeutics by 1,649.8% during the 1st quarter. DV Trading LLC now owns 423,566 shares of the company’s stock valued at $2,241,000 after purchasing an additional 399,359 shares in the last quarter. Parallel Advisors LLC bought a new stake in shares of Compass Therapeutics in the 1st quarter worth $28,000. Bank of America Corp DE raised its stake in shares of Compass Therapeutics by 224.9% in the 1st quarter. Bank of America Corp DE now owns 865,613 shares of the company’s stock worth $4,579,000 after buying an additional 599,179 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Compass Therapeutics in the first quarter valued at $294,000. Finally, California State Teachers Retirement System lifted its holdings in shares of Compass Therapeutics by 1,294.2% in the first quarter. California State Teachers Retirement System now owns 112,316 shares of the company’s stock valued at $594,000 after buying an additional 104,260 shares during the period. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Price Performance

Shares of CMPX opened at $1.91 on Friday. Compass Therapeutics, Inc. has a one year low of $1.61 and a one year high of $6.88. The company has a 50-day moving average of $2.12 and a two-hundred day moving average of $3.99. The stock has a market cap of $343.97 million, a price-to-earnings ratio of -4.66 and a beta of 0.90.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). Analysts anticipate that Compass Therapeutics, Inc. will post -0.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CMPX. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a report on Friday, July 17th. D. Boral Capital restated a “buy” rating and set a $30.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 27th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 28th. Finally, Raymond James Financial downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Compass Therapeutics has an average rating of “Moderate Buy” and an average price target of $12.25.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.